A trial to compare the viral suppressive efficacy of tenofovir disoproxil fumarate (TDF) mono-rescue therapy (TDF group) and TDF plus entecavir (ETV) combination-rescue therapy (TDF + ETV group) in chronic hepatitis B (CHB) patients with lamivudine resistance (LAM-R) and ETV resistance (ETV-R)
Latest Information Update: 12 May 2016
At a glance
- Drugs Entecavir (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
Most Recent Events
- 12 May 2016 New trial record
- 17 Apr 2016 Results presented at The International Liver Congress 2016